PROTAGONIST THERAPEUTICS

Serial Number 98319346
730

Registration Progress

Application Filed
Dec 18, 2023
Under Examination
Oct 22, 2024
Approved for Publication
Aug 27, 2024
Published for Opposition
Aug 27, 2024
Registered

Attorney Assistance

Statement of Use Due - Extension 1 Granted
Due: Oct 22, 2025 105 days

Basic Information

Serial Number
98319346
Deadline
October 22, 2025
Description
Statement of Use or 2nd Extension Due
Filing Date
December 18, 2023
Published for Opposition
August 27, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Apr 15, 2025
Application
Pending
Classes
005 042 044

Rights Holder

Protagonist Therapeutics, Inc.

03
Address
7707 Gateway Blvd. Suite 210
Newark, CA 94560

Ownership History

Protagonist Therapeutics, Inc.

Original Applicant
03
Newark, CA

Protagonist Therapeutics, Inc.

Owner at Publication
03
Newark, CA

Legal Representation

Attorney
Frances M. Jagla

USPTO Deadlines

Next Deadline
105 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
October 22, 2025
Extension Available
Until October 22, 2025

Application History

16 events
Date Code Type Description
Apr 16, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 15, 2025 EX1G S SOU EXTENSION 1 GRANTED
Apr 15, 2025 EXT1 S SOU EXTENSION 1 FILED
Apr 15, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 22, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 27, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 27, 2024 PUBO A PUBLISHED FOR OPPOSITION
Aug 7, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 18, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 17, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 17, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN
Jul 17, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED
Jul 17, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED
Jul 16, 2024 DOCK D ASSIGNED TO EXAMINER
Mar 25, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 18, 2023 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of oncological, hematological, inflammatory and autoimmune disorders, rare and orphan disorders, endocrine disorders
Class 042
Scientific and medical research relating to oncological, hematological, inflammatory and autoimmune disorders, rare and orphan disorders, endocrine disorders
Class 044
Providing online healthcare and medical information to patients and healthcare providers relating to oncological, hematological, inflammatory and autoimmune disorders, rare and orphan disorders, endocrine disorders

Classification

International Classes
005 042 044

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"